Previous research and current findings sum up a positive sign on allogeneic stem cell transplantation (ASCT) or doner stem cell transplantation for a significant survival benefit among patients with intermediate- and poor-risk but not good-risk acute myeloid leukemia (AML) in first complete remission.
According to an article in the June 10 issue of JAMA, researchers claimed that compared with nonallogeneic stem cell tranplantation, allogeneic SCT is much more effective for leukemia patients.
John Koreth, M.B.B.S., D.Phil., of the Dana Farber Cancer Institute, Boston, and colleagues conducted a meta-analysis to quantify relapse-free survival (RFS) and overall survival benefit of allogeneic SCT for AML in CR1 overall, and also for good-, intermediate-, and poor-risk AML.
The researchers conducted a search for articles on trials evaluating allogeneic SCT vs. nonallogeneic SCT therapies (autologous [donor and recipient are the same person] SCT, consolidation chemotherapy, or both) for AML in CR1.
The researchers tracked 24 trials to determine the best treatment for individual patients, which included 6,007 patients (5,951 patients in RFS analyses and 5,606 patients in overall survival analyses).
3,638 patients were analyzed by cytogenetic (abnormalities in the composition of the chromosomes) risk (547, 2,499, and 592 with good-, intermediate-, and poor-risk AML, respectively).
They looked at the relapse-free survival and the benefit of allogeneic stem-cell transplantation vs. nonallogeneic stem-cell transplantation, plus chemotherapy for patients who had good, intermediate or poor survival risk.
As per their primary findings the totality of the prospective trial data indicates statistically significant RFS and overall survival benefit with allogeneic SCT for adult AML in CR1.
Researchers found significant RFS and overall survival benefit for allogeneic SCT in intermediate. It is observed that People in all risk groups, but especially those with poor and intermediate risk of survival, benefit most. Patients were more likely to survive and less likely to suffer a relapse over the long term than patients given alternative therapies.
Researchers believed that the results of this latest review could lead to a new standard of care for patients with acute myeloid leukemia (AML).
AML is the most common form of acute leukemia, striking almost 12,000 adults a year in the United States. Still now best subsequent therapy to prolong disease-free survival has been unclear. The only treatment to achieve a first remission is chemitherapy.